Despite existing studies demonstrating some benefits of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure, most randomized controlled trials (RCTs) have been limited to comparisons of single or a few medications, lacking comprehensive evaluations across multiple drug classes. Here, SLC5A2 is linked to heart failure.